D

    Dyne Therapeutics Inc (DYN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.43
    +0.36 (+1.44%)

    Market Cap: $4.68B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    37%(11/30)
    Avg Surprise
    -89.26%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.88
    Range$-1.03 - $-0.73
    13 analysts
    EPS RevisionsNo revisions (7d)
    1
    8
    30d
    EPS Estimate Drift
    90d ago$-0.76+13.8%
    60d ago$-0.76+13.5%
    30d ago$-0.77+12.9%
    7d ago$-0.87+1.0%
    Current$-0.88
    Revenue Consensus
    $0
    Range$0 - $0
    15 analysts
    Dec 31, 2026
    EPS Consensus$-1.16
    Range$-1.53 - $-0.75
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.16---
    Sep 26EST
    		-$-0.88---
    Jun 26
    		$-1.08$-0.74-45.95%Miss-11.3%
    Mar 26
    		$-0.73$-0.78+6.41%Beat+30.5%
    Dec 25
    		$-0.73$-0.77+5.48%Beat+17.0%
    Sep 25
    		$-0.76$-0.81+6.17%Beat+20.8%
    Jun 25
    		$-0.97$-0.93-4.30%Miss-38.6%
    Mar 25
    		$-1.05$-0.84-25.00%Miss-29.6%
    Dec 24
    		$-0.88$-0.91+3.51%Beat+19.3%
    Sep 24
    		$-0.96$-0.71-35.21%Miss+3.0%
    Jun 24
    		$-0.70$-0.72+2.78%Beat+35.2%
    Mar 24
    		$-0.81$-0.80-1.25%Miss-3.8%
    Dec 23
    		$-1.09$-0.93-17.20%Miss-47.3%
    Sep 23
    		$-0.99$-0.76-30.26%Miss-23.7%
    Jun 23
    		$-1.08$-0.78-38.46%Miss-6.9%
    Mar 23
    		$-0.78$-0.76-2.63%Miss-13.0%
    Dec 22
    		$-0.74$-0.84+11.90%Beat+26.0%
    Sep 22
    		$-0.80$-0.92+13.04%Beat+3.6%
    Jun 22
    		$-1.01$-0.80-26.25%Miss-74.1%
    Mar 22
    		$-0.69$-0.88+21.59%Beat-38.0%
    Dec 21
    		$-1.00$-0.97-3.09%Miss-56.3%
    Sep 21
    		$-0.83$-0.66-25.76%Miss-167.7%
    Jun 21
    		$-0.58$-0.55-5.45%Miss-48.7%
    Mar 21
    		$-0.50$-0.62+19.35%Beat-42.9%
    Dec 20
    		$-0.64$-0.37-72.97%Miss-306.5%
    Sep 20
    		$-0.31$-0.39+20.51%Beat+72.3%
    Jun 20
    		$-0.39$0.00N/AMiss+68.5%
    Dec 17
    		$-0.35$-0.42+16.67%Beat+75.0%
    Sep 17
    		$0.31$0.55-43.64%Miss+203.3%
    Jun 17
    		$-1.12$-0.71-57.75%Miss-
    Mar 17
    		$-1.24$-0.11-1027.27%Miss-
    Dec 16
    		$-1.40$0.14-1100.00%Miss-
    Sep 16
    		$-0.30$0.21-242.86%Miss-

    Key Metrics

    Valuation
    P/E Ratio-7.71EV/EBITDA-8.87x
    Price/FCF-8.43xFCF Yield-11.87%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-81.60%ROIC-47.08%
    Financial Health
    Debt/Equity0.28xInterest CoverageN/A
    Current Ratio12.02xQuick Ratio12.02x
    Trading Statistics
    Beta1.08Avg Volume1.77M
    52-Week High$27.3052-Week Low$11.92

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.01
    SMA 20$26.08
    SMA 50$24.41
    SMA 200$19.80
    EMA 10$25.86
    EMA 20$25.72
    EMA 50$24.26
    EMA 200$20.06

    MACD

    Line: 0.38Signal: 0.63Hist: -0.24

    ADX

    ADX: 19.7+DI: 20.9-DI: 24.5

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down12.0
    PSAR$26.67

    Bollinger Bands

    Upper Band$26.87
    Lower Band$25.29
    %B Position603%(Upper)
    Band Width0.09

    RSI (14-Day)

    Neutral
    49.9

    Momentum Oscillators

    Stoch %K28.3
    Stoch %D38.9
    Williams %R-68.8
    ROC (10d)-2.8%
    Momentum-0.72
    CCI (20d)-184.8
    MFI (14d)26.8

    Volatility Measures

    ATR (14d)$1.04(4.1%)
    StdDev (20d)0.39
    Hist Vol28.5%(Moderate)

    Volume Flow

    VWAP$25.22
    OBV76.2M
    AD Line-1.1M
    CMF (20d)0.128

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.5x
    VWMA (20d)$26.09

    Pivot Points

    R3$26.91
    R2$26.44
    R1$25.76
    Pivot Point$25.29
    S1$24.61
    S2$24.14
    S3$23.46

    Advanced Oscillators

    TSI12.90
    Ultimate Osc51.3
    KST66.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.57M$0$0$0$3.79M$0
    Cost of Revenue$0$0$521,000$0$0$0N/A$0$0$0$567,000$0
    Gross Profit$0$0$-521,000$0$0$0$786,000$0$0$0$3.22M$0
    Operating Expenses$181.66M$125.28M$116.13M$113.89M$115.79M$122.37M$97.11M$105.66M$71.96M$69.16M$67.69M$62.27M
    R&D$152.17M$100.89M$95.43M$97.22M$99.24M$106.45M$81.80M$92.80M$62.26M$44.54M$58.84M$55.25M
    SG&A$29.49M$24.39M$20.70M$16.67M$16.55M$15.93M$15.30M$12.86M$9.70M$24.62M$8.84M$7.02M
    Operating Income$-181,661,000$-125,276,000$-116,129,000$-113,892,000$-115,791,000$-122,372,000$-97,198,000$-105,569,000$-71,962,000$-69,157,000$-67,689,000$-62,273,000
    Interest Income$7.79M$8.76M$7.66M$8.48M$6.63M$7.10M$7.59M$9.28M$7.05M$3.00M$1.75M$2.19M
    Interest Expense$4.59M$4.20M$0$2.90M$94,000$0$0$0$0$0$0$0
    Income Before Tax$-178,556,000$-120,854,000$-111,955,000$-108,041,000$-110,857,000$-115,361,000$-89,632,000$-97,035,000$-65,102,000$-65,649,000$-66,638,000$-60,210,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-178,556,000$-120,854,000$-111,955,000$-108,041,000$-110,857,000$-115,361,000$-89,542,000$-97,125,000$-65,102,000$-65,649,000$-66,638,000$-60,210,000
    EBITDA$-181,189,000$-124,859,000$-116,286,000$-113,458,000$-117,348,000$-122,575,000$-97,610,000$-106,849,000$-71,755,000$-68,265,000$-68,185,000$-62,333,000
    EBIT$-181,749,000$-125,409,000$-116,419,000$-113,613,000$-117,388,000$-122,461,000$-97,224,000$-106,311,000$-72,154,000$-68,651,000$-68,390,000$-62,399,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DYN

    News

    How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story

    Dyne Therapeutics (DYN) received U.S. FDA clearance to begin a Phase 1 trial for DYNE-302, expanding its FORCE platform to a third clinical program for facioscapulohumeral muscular dystrophy. This development, alongside a recent US$375.15 million equity raise, impacts the company's investment narrative and risk profile. While the FDA clearance adds a new potential value driver, it also increases R&D expenses, contributing to a net loss of US$178.56 million in Q2.

    Sahm•8/23/26•
    Somewhat-Bullish

    Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN

    Royal Bank of Canada significantly increased its stake in Dyne Therapeutics by 267.6% in the first quarter, acquiring an additional 49,641 shares to reach a total holding of 68,188 shares valued at $1.24 million. Despite institutional investors owning a large portion of the company (96.68%), Dyne Therapeutics reported a larger-than-expected quarterly loss of $1.08 per share. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $34.42, although insider activity shows substantial selling compared to buying over the past 90 days.

    MarketBeat•8/21/26•
    Neutral

    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dyne Therapeutics, Inc. announced the grant of inducement equity awards to 11 newly hired employees, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for 161,300 shares and restricted stock units for 51,200 shares, both vesting over four years. The grants are intended to attract and retain talent for the clinical-stage company focused on genetically driven neuromuscular diseases.

    Yahoo Finance•8/20/26•
    Somewhat-Bullish

    Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN

    Handelsbanken Fonder AB recently acquired 53,200 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $1.18 million, contributing to institutional investors owning 96.68% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $34.42, despite the company reporting a wider-than-expected quarterly loss and significant insider selling.

    MarketBeat•8/20/26•
    Neutral

    Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds

    Dyne Therapeutics director Jason P. Rhodes, through Atlas Venture-affiliated funds, indirectly sold 2,586,928 shares of DYN common stock on August 13-14, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on July 13, 2026, with weighted average prices ranging from approximately $25.00 to $26.20 per share. Rhodes disclaims beneficial ownership of these shares except for his pecuniary interest.

    Stock Titan•8/18/26•
    Bearish

    Frequently Asked Questions About DYN

    Does DYN pay dividends?
    Dyne Therapeutics Inc (DYN) does not currently pay a regular dividend.
    What is DYN's market cap?
    Dyne Therapeutics Inc (DYN) has a market capitalization of $4.68B with a current stock price of $25.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In